📄 medicine

Early addition of nintedanib in acute exacerbation of fibrotic interstitial lung disease: a single-center retrospective cohort study

This single-center retrospective cohort study suggests that early add-on nintedanib, initiated during hospitalization for acute exacerbation of fibrotic interstitial lung disease, is associated with improved 28-day mortality and gas-exchange recovery, particularly in patients presenting with severe hypoxemia (PaO₂/FiO₂ < 200), although this benefit did not extend to 90-day survival.

Original authors: Takashi Yamana, Risa Yoshioka, Yusuke Mizuhashi, Kasumi Tsukamoto, Hiroaki Kodama, Yukiko Abe, Mitsuhiro Kamimura

Published 2026-09-20

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Takashi Yamana, Risa Yoshioka, Yusuke Mizuhashi, Kasumi Tsukamoto, Hiroaki Kodama, Yukiko Abe, Mitsuhiro Kamimura

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

The lungs are designed to be soft, spongy, and full of tiny air sacs that allow oxygen to pass into the blood. In a group of conditions known as fibrotic interstitial lung disease, this delicate tissue slowly turns into stiff scar tissue, much like a sponge that has been hardened by years of use. For patients living with this chronic scarring, the most dangerous moment is not the slow decline itself, but a sudden, catastrophic event called an acute exacerbation. During such an event, the lungs deteriorate rapidly over just days, filling with fluid and inflammation that makes breathing nearly impossible. This crisis carries a grim reality: nearly half of the people who suffer one do not survive the first few months. For decades, doctors have had no proven way to stop this rapid collapse, relying only on powerful steroids to calm the inflammation, often with little success.

A team of researchers at the National Disaster Medical Center in Tokyo recently investigated whether a drug already approved for managing stable lung scarring could also save lives during these sudden crises. Nintedanib is a medication that works by blocking signals that tell the body to build scar tissue. While it is known to slow the progression of the disease when a patient is stable, no one knew if starting it during a life-threatening emergency would help or if the lungs were too damaged to respond. The researchers looked back at the medical records of 75 patients who were hospitalized for this specific type of lung crisis between 2023 and 2026. They compared the outcomes of those who received the standard steroid treatment alone against those who also received nintedanib added to their care, carefully tracking who survived and how their breathing improved over time.

The study revealed a striking pattern, particularly for the patients who arrived at the hospital in the most critical condition. Among those whose blood oxygen levels were dangerously low upon admission, the addition of nintedanib made a profound difference in the first month. In this severe group, nearly 70 percent of the patients who received only standard care died within 28 days. In contrast, only about 17 percent of the patients who received the added drug died in that same period. The data suggests that for these critically ill individuals, the drug helped stabilize their condition quickly enough to prevent early death. The researchers observed that patients who received the drug often showed a measurable improvement in their ability to absorb oxygen within three days of starting treatment, a sign that the lungs were beginning to recover function.

However, the story of the drug's effectiveness is nuanced and depends heavily on the timing and the severity of the illness. The researchers found that the survival benefit was most visible in the first 28 days. By the time 90 days had passed, the difference in survival rates between the two groups had narrowed, with the overall death rates becoming similar. This suggests that while the drug may buy crucial time and prevent early collapse, it does not necessarily change the long-term outcome for everyone, as many patients eventually succumb to other complications or the underlying severity of their disease. The study also noted that the drug was generally safe to use even in these sick patients, with side effects like mild diarrhea or temporary liver enzyme changes being manageable and rarely forcing doctors to stop the treatment.

One of the most important aspects of this research was how the scientists handled the fact that the drug was not given to everyone immediately upon admission. In many cases, doctors waited several days to start the medication, perhaps to see if the patient would stabilize first. If the researchers had simply compared the final outcomes without accounting for this delay, the results could have been misleading, making the drug look more effective than it truly was because the patients had to survive long enough to even receive it. By using a sophisticated method that treated the drug as a variable that changed over time, the team confirmed that the early survival benefit was real and not just a statistical trick. The findings were strongest for those with the lowest oxygen levels, suggesting that the drug might be a vital tool specifically for the most desperate cases, rather than a universal cure for all lung crises.

Ultimately, this study offers a glimmer of hope for a condition that has long been considered untreatable in its most violent form. It indicates that adding nintedanib to standard care can significantly improve the chances of surviving the first month of a severe lung exacerbation, especially for patients who are struggling the most to breathe. While the drug did not eliminate the risk of death entirely over a longer period, the ability to keep patients alive through the initial, most dangerous phase is a significant medical advance. The researchers conclude that these findings warrant further investigation through planned clinical trials to confirm the results and to determine the best way to use this treatment for those facing the most severe respiratory failure.

Technical Summary: Early Addition of Nintedanib in Acute Exacerbation of Fibrotic Interstitial Lung Disease

Problem Statement
Acute exacerbation of fibrotic interstitial lung disease (AE-ILD) is a devastating complication characterized by rapid respiratory worsening and new bilateral ground-glass opacities superimposed on pre-existing fibrosis. It carries a short-term mortality rate approaching 50%, with no established disease-modifying therapies currently available. While high-dose corticosteroids remain the standard of care, they lack proven survival benefits in randomized trials. Nintedanib, an intracellular tyrosine kinase inhibitor approved for stable fibrotic ILD, effectively reduces the risk of exacerbations and slows lung function decline in chronic settings. However, its therapeutic utility, optimal target population, and physiological impact when initiated during an active acute exacerbation remain undefined.

Methodology
This single-center, retrospective cohort study was conducted at the National Disaster Medical Center in Tokyo, Japan, between April 2023 and February 2026. The study evaluated 75 consecutive adult patients hospitalized with AE-ILD, comprising 26 patients who received add-on nintedanib and 49 patients who received standard therapy alone (intravenous corticosteroid pulse therapy).

Study Design & Bias Control: To address the "immortal time bias" inherent in observational studies where treatment initiation occurs days after admission (median 7 days), the primary analysis modeled nintedanib exposure as a time-varying covariate in a Cox proportional hazards model. Person-time prior to the first dose was allocated to the unexposed state.
Subgroup Analysis: A predefined high-risk subgroup of patients presenting with severe hypoxemia (PaO₂/FiO₂ < 200 on admission) was analyzed separately.
Endpoints: The primary endpoint was 90-day all-cause mortality. Secondary endpoints included 28-day all-cause mortality and serial PaO₂/FiO₂ ratios measured at baseline (pre-dose), 72 hours, and 7 days post-initiation.
Statistical Approach: Due to the violation of proportional hazards assumptions, time-split modeling was performed (days 0–28 and days 29–90). Sensitivity analyses included landmark analyses and alternative exclusion criteria to further validate findings against immortal time bias.

Key Results

Physiological Recovery: In the nintedanib group, oxygenation showed progressive improvement following initiation. The median PaO₂/FiO₂ ratio increased from 200 pre-dose to 222 at 72 hours and 303 at 7 days ( $p < 0.001$ ). Crucially, the trajectory of oxygenation at 72 hours strongly stratified 28-day survival: survivors exhibited a median increase of +40.5, while non-survivors showed a decrease of −19.0 ( $p = 0.035$ ).
Mortality Outcomes (Unadjusted): Unadjusted 28-day mortality was significantly lower in the nintedanib group compared to controls (19.2% vs. 44.9%; $p = 0.042$ ). This effect was most pronounced in the severe hypoxemia subgroup (PaO₂/FiO₂ < 200), where mortality was 16.7% vs. 69.6% ( $p = 0.001$ ).
Mortality Outcomes (Bias-Adjusted):
- Overall Cohort: In the time-varying Cox model over 90 days, the adjusted hazard ratio (aHR) was 0.78 (95% CI, 0.34–1.80), which was not statistically significant.
- Severe Hypoxemia Subgroup: When the analysis was restricted to the first 28 days (where the proportional hazards assumption held and events were concentrated), nintedanib was associated with a significantly lower mortality risk in patients with PaO₂/FiO₂ < 200 (aHR, 0.23; 95% CI, 0.06–0.82; $p = 0.024$ ).
- 90-Day Mortality: There was no significant difference in 90-day mortality between groups overall (38.5% vs. 44.9%) or within the severe subgroup (44.4% vs. 69.6%, $p = 0.125$ ). The temporal analysis revealed that all control deaths occurred within the first 28 days, whereas nintedanib-treated patients experienced delayed mortality (50% of deaths occurred after day 28), suggesting a mortality displacement effect rather than a long-term survival benefit in this cohort.
Safety: Nintedanib was generally well-tolerated. Adverse events were predominantly mild-to-moderate (diarrhea, anorexia, elevated liver enzymes). Only one patient (4.0%) discontinued treatment due to an adverse event (grade 2 liver enzyme elevation). No grade $\ge$ 3 gastrointestinal or hepatic toxicities were observed.

Significance and Claims
The authors conclude that early add-on nintedanib in AE-ILD is associated with progressive gas-exchange recovery and a significant reduction in 28-day mortality, particularly among patients presenting with severe hypoxemia (PaO₂/FiO₂ < 200).

The study highlights that:

Target Population: The therapeutic signal is specific to patients with severe initial respiratory failure; no benefit was observed in patients with PaO₂/FiO₂ $\ge$ 200.
Mechanism of Action: The rapid physiological improvement (within 72 hours) supports the hypothesis that nintedanib's anti-inflammatory and anti-fibroproliferative mechanisms can modulate alveolar-capillary gas exchange on a timescale of days, rather than months.
Prognostic Utility: The 72-hour change in PaO₂/FiO₂ ratio serves as a potential early biomarker for 28-day survival and could act as a surrogate endpoint in future trials.
Limitations of Long-Term Benefit: While the early survival advantage is robust after accounting for immortal time bias, it did not translate into a 90-day mortality difference, likely due to late mortality displacement driven by non-pulmonary comorbidities in frail, elderly patients.

The paper asserts that these findings warrant prospective trials focusing on early initiation protocols specifically for high-risk patients with severe hypoxemia, utilizing combined physiological and short-term survival endpoints.

More like this